EUVIMEDEUVIMED entdecken
Crossref

The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review

Sarah Jenkins, Michael Hunter

International Journal of Clinical Pharmacy and Medicine · 16.11.2026

DOI: 10.68760/s2026146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy and Medicine, online erschienen am 16.11.2026. Verfasst von Sarah Jenkins und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Jenkins, S., & Hunter, M. (2026). The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review. International Journal of Clinical Pharmacy and Medicine. https://doi.org/10.68760/s2026146

Vancouver

Jenkins S, Hunter M. The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review. International Journal of Clinical Pharmacy and Medicine. 2026. doi:10.68760/s2026146

BibTeX
@article{Jenkins2026,
  author = {Jenkins, Sarah and Hunter, Michael},
  title = {The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review},
  journal = {International Journal of Clinical Pharmacy and Medicine},
  year = {2026},
  doi = {10.68760/s2026146}
}
Kostenlos starten →